Nastech Pharmaceutical Company Inc. Named One Of The Pacific Northwest's Fastest Growing Life Sciences Companies In Deloitte's Technology Fast 50 Program
BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for the Pacific Northwest, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in Washington, Oregon and Idaho by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth during the five years from 2001-2005.
"We are proud to be recognized as one of the fastest growing life sciences companies in the Pacific Northwest," said Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. "This attests to the significant advances in our technologies, clinical programs and partnerships that are taking place at Nastech."
"To rank on Deloitte's Technology Fast 50, companies must have phenomenal revenue growth during the five year period," said Larry Hile, a Partner in Deloitte's Technology, Media & Telecommunications (TMT) industry practice based in Seattle. "Nastech Pharmaceutical has proven to be one of the fast-growth success stories in the Pacific Northwest, and we applaud their dedication to making their vision a reality."
Nastech increased revenue by 186 percent from 2001 to 2005 to qualify for inclusion in the Technology Fast 50 for the Pacific Northwest.
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.
About Nastech
Nastech is a pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, diabetes, obesity, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.
CONTACTS: Nastech Ed Bell Senior Investor Relations Manager (425) 908-3639 ir@nastech.com Noonan Russo Matthew Haines (Investors/Media) (212) 845-4235
Nastech Pharmaceutical Company Inc.CONTACT: Ed Bell, Senior Investor Relations Manager of Nastech,+1-425-908-3639, ir@nastech.com; or Investors-Media: Matthew Haines ofNoonan Russo, +1-212-845-4235, for Nastech